Attached files
| file | filename |
|---|---|
| EX-31.3 - EX-31.3 - CYTOKINETICS INC | cytk-ex313_6.htm |
| EX-31.2 - EX-31.2 - CYTOKINETICS INC | cytk-ex312_8.htm |
| EX-31.1 - EX-31.1 - CYTOKINETICS INC | cytk-ex311_10.htm |
| EX-10.1 - EX-10.1 - CYTOKINETICS INC | cytk-ex101_331.htm |
| 10-Q - 10-Q - CYTOKINETICS INC | cytk-10q_20170930.htm |
Exhibit 32.1
PURSUANT TO
18. U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
I certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report of Cytokinetics, Incorporated on Form 10-Q for the quarterly period ended September 30, 2017 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in such Form 10-Q fairly presents in all material respects the financial condition and results of operations of Cytokinetics, Incorporated.
Dated: November 3, 2017
|
|
/s/ Robert I. Blum |
|
|
Robert I. Blum |
|
|
President and Chief Executive Officer (Principal Executive Officer) |
|
|
|
|
|
/s/ Ching Jaw |
|
|
Ching Jaw |
|
|
Senior Vice President, Chief Financial Officer (Principal Financial Officer) |
|
|
|
|
|
/s/ Peter S. Roddy |
|
|
Peter S. Roddy |
|
|
Senior Vice President, Chief Accounting Officer (Principal Accounting Officer) |